Demographics and transplant-related characteristics of SAA patients by IBMFS-associated variant status categories
| Variable . | No Variant (n = 611) . | Carrier (n = 73) . | Unrecognized IBMFS (n = 48) . | P* . |
|---|---|---|---|---|
| Recipient age at transplant (yr), n (%) | .19 | |||
| ≤10 | 119 (19) | 15 (21) | 16 (33) | |
| >10, ≤20 | 181 (30) | 21 (29) | 16 (33) | |
| >20, ≤40 | 196 (32) | 23 (32) | 13 (27) | |
| >40 | 115 (19) | 14 (19) | 3 (6) | |
| Recipient sex, n (%) | .65 | |||
| Male | 340 (56) | 44 (60) | 25 (52) | |
| Female | 271 (44) | 29 (40) | 23 (48) | |
| Recipient race, n (%)† | .60 | |||
| Caucasian | 477 (78) | 60 (83) | 37 (77) | |
| Other | 131 (22) | 12 (17) | 11 (23) | |
| Karnofsky Performance Score, n (%)† | .81 | |||
| 10-80 | 126 (25) | 16 (28) | 8 (22) | |
| 90-100 | 369 (75) | 42 (72) | 29 (78) | |
| Donor type, n (%) | .94 | |||
| Related donor | 80 (13) | 9 (12) | 7 (15) | |
| Unrelated donor | 531 (87) | 64 (88) | 41 (85) | |
| Stem cell source, n (%)† | .20 | |||
| BM | 501 (82) | 66 (90) | 40 (83) | |
| Unknown | 109 (18) | 7 (10) | 8 (17) | |
| GvHD prophylaxis, n (%)† | .23‡ | |||
| Tacrolimus-based | 254 (42) | 37 (51) | 14 (29) | |
| CSA-based | 289 (47) | 32 (44) | 26 (54) | |
| Other | 61 (10) | 4 (5) | 8 (17) | |
| No GvHD prophylaxis | 6 (1) | 0 (0) | 0 (0) | |
| Conditioning regimen, n (%) | .85‡ | |||
| Myeloablative | 230 (38) | 29 (40) | 21 (44) | |
| RIC/nonmyeloablative | 377 (62) | 44 (60) | 27 (56) | |
| Other | 4 (1) | 0 (0) | 0 (0) | |
| Donor age at transplant (yr), n (%)† | .83 | |||
| ≤30 | 237 (42) | 30 (44) | 22 (50) | |
| >30, ≤40 | 164 (29) | 21 (31) | 10 (23) | |
| >40 | 158 (28) | 17 (25) | 12 (27) | |
| Donor sex, n (%)† | .56 | |||
| Male | 404 (67) | 51 (70) | 29 (60) | |
| Female | 202 (33) | 22 (30) | 19 (40) | |
| Donor/recipient CMV serostatus, n (%) | .20 | |||
| Donor negative/recipient negative | 167 (27) | 15 (21) | 16 (33) | |
| Donor negative/recipient positive | 181 (30) | 25 (34) | 12 (25) | |
| Donor positive/recipient negative | 72 (12) | 5 (7) | 8 (17) | |
| Donor positive/recipient positive | 149 (24) | 26 (36) | 9 (19) | |
| Unknown | 42 (7) | 2 (3) | 3 (6) | |
| Number of matches for HLA, n (%)†,§ | .31 | |||
| 8/8 | 335 (65) | 39 (63) | 22 (54) | |
| ≤7/8 | 177 (35) | 23 (37) | 19 (46) | |
| Year of transplant, n (%)† | .21 | |||
| 1989-2005 | 206 (34) | 27 (37) | 21 (44) | |
| 2006-2010 | 209 (34) | 17 (23) | 15 (31) | |
| 2011-2015 | 195 (32) | 29 (40) | 12 (25) |
| Variable . | No Variant (n = 611) . | Carrier (n = 73) . | Unrecognized IBMFS (n = 48) . | P* . |
|---|---|---|---|---|
| Recipient age at transplant (yr), n (%) | .19 | |||
| ≤10 | 119 (19) | 15 (21) | 16 (33) | |
| >10, ≤20 | 181 (30) | 21 (29) | 16 (33) | |
| >20, ≤40 | 196 (32) | 23 (32) | 13 (27) | |
| >40 | 115 (19) | 14 (19) | 3 (6) | |
| Recipient sex, n (%) | .65 | |||
| Male | 340 (56) | 44 (60) | 25 (52) | |
| Female | 271 (44) | 29 (40) | 23 (48) | |
| Recipient race, n (%)† | .60 | |||
| Caucasian | 477 (78) | 60 (83) | 37 (77) | |
| Other | 131 (22) | 12 (17) | 11 (23) | |
| Karnofsky Performance Score, n (%)† | .81 | |||
| 10-80 | 126 (25) | 16 (28) | 8 (22) | |
| 90-100 | 369 (75) | 42 (72) | 29 (78) | |
| Donor type, n (%) | .94 | |||
| Related donor | 80 (13) | 9 (12) | 7 (15) | |
| Unrelated donor | 531 (87) | 64 (88) | 41 (85) | |
| Stem cell source, n (%)† | .20 | |||
| BM | 501 (82) | 66 (90) | 40 (83) | |
| Unknown | 109 (18) | 7 (10) | 8 (17) | |
| GvHD prophylaxis, n (%)† | .23‡ | |||
| Tacrolimus-based | 254 (42) | 37 (51) | 14 (29) | |
| CSA-based | 289 (47) | 32 (44) | 26 (54) | |
| Other | 61 (10) | 4 (5) | 8 (17) | |
| No GvHD prophylaxis | 6 (1) | 0 (0) | 0 (0) | |
| Conditioning regimen, n (%) | .85‡ | |||
| Myeloablative | 230 (38) | 29 (40) | 21 (44) | |
| RIC/nonmyeloablative | 377 (62) | 44 (60) | 27 (56) | |
| Other | 4 (1) | 0 (0) | 0 (0) | |
| Donor age at transplant (yr), n (%)† | .83 | |||
| ≤30 | 237 (42) | 30 (44) | 22 (50) | |
| >30, ≤40 | 164 (29) | 21 (31) | 10 (23) | |
| >40 | 158 (28) | 17 (25) | 12 (27) | |
| Donor sex, n (%)† | .56 | |||
| Male | 404 (67) | 51 (70) | 29 (60) | |
| Female | 202 (33) | 22 (30) | 19 (40) | |
| Donor/recipient CMV serostatus, n (%) | .20 | |||
| Donor negative/recipient negative | 167 (27) | 15 (21) | 16 (33) | |
| Donor negative/recipient positive | 181 (30) | 25 (34) | 12 (25) | |
| Donor positive/recipient negative | 72 (12) | 5 (7) | 8 (17) | |
| Donor positive/recipient positive | 149 (24) | 26 (36) | 9 (19) | |
| Unknown | 42 (7) | 2 (3) | 3 (6) | |
| Number of matches for HLA, n (%)†,§ | .31 | |||
| 8/8 | 335 (65) | 39 (63) | 22 (54) | |
| ≤7/8 | 177 (35) | 23 (37) | 19 (46) | |
| Year of transplant, n (%)† | .21 | |||
| 1989-2005 | 206 (34) | 27 (37) | 21 (44) | |
| 2006-2010 | 209 (34) | 17 (23) | 15 (31) | |
| 2011-2015 | 195 (32) | 29 (40) | 12 (25) |